The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.
Qualitative research based on semi-structured interviews conducted with patients diagnosed with age-related macular degeneration (AMD), followed in the ophthalmology department of Nantes University Hospital and treated with intravitreal injections. These interviews are structured around three main themes in order to better understand: The experience and perception of the current treatment by the patients Their perceptions, expectations, and potential concerns regarding gene therapy Their perception and understanding of decision-making autonomy in their health decisions
Study Type
OBSERVATIONAL
Enrollment
30
The experience and current treatment outcomes perceived by patients
Semi-structured interviews
Time frame: 1 months
Patients' perceptions, expectations, and potential concerns regarding gene therapy
Semi-structured interviews
Time frame: 1 month
Patients' perception and representation of decisional autonomy in their health decisions
Semi-structured interviews
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.